MHRA-100676-PIP01-22-M01 (update)

Key Facts

PIPS Key Facts
Active Substance
  • EMTRICITABINE
  • TENOFOVIR ALAFENAMIDE FUMARATE
Invented Name
  • Descovy
  • Descovy
PIP Number MHRA-100676-PIP01-22-M01 (update)
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral formulation
Therapeutic area
Therapeutic area:
  • Infectious diseases
Conditions / Indications
Conditions / Indications:
  • Treatment of human immunodeficiency virus (HIV-1) infection.
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):EMTRICITABINETENOFOVIR ALAFENAMIDE FUMARATE.pdf
Published Date 24/08/2023